Online inquiry

IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4256MR)

This product GTTS-WQ4256MR is a type of mRNA modified with 2-Thio-UTP, which ecodes the monoclonal antibody that targets Factor VIII substitute gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000132.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2157
UniProt ID P00451
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ4256MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6088MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ8653MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ8242MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HLX-06
GTTS-WQ11469MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ10302MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ3777MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ6529MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CX-191
GTTS-WQ3230MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARGX-113
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW